Methadone News and Research

RSS

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

3 Dec 2011

Combination of other opioids with methadone therapy can lead to overdose or fatal consequences

A new study has shown harmful prescription patterns of powerful painkillers among a substantial number of Ontario patients who received methadone therapy to treat their opioid addiction.

29 Nov 2011

APS supports CDC's call for multifaceted approach to address prescription drug misuse

As reported by the U.S Centers for Disease Control, some 15,000 deaths occurred in the U.S. in 2008 from overdoses of prescription pain medications, and demand for treatment of prescription opioid addiction increased almost six fold between 1999 and 2009.

10 Nov 2011

NIH announces results from first large scale study on treatment of prescription opioid addiction

People addicted to prescription painkillers reduce their opioid abuse when given sustained treatment with the medication buprenorphine plus naloxone (Suboxone), according to research published in yesterday's Archives of General Psychiatry and conducted by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.

9 Nov 2011

First large-scale study to address treatment of prescription opioid addiction

Individuals addicted to prescription painkillers are more likely to succeed in treatment with the aid of the medication buprenorphine-naloxone (Suboxone), report McLean Hospital and Harvard Medical School researchers in today's online edition of the Archives of General Psychiatry.

8 Nov 2011

Tibotec to present results of TMC435 phase 2b study on HCV at AASLD 2011

Tibotec Pharmaceuticals (Tibotec), one of the Janssen (Janssen) Pharmaceutical Companies, today will present results of the final analysis of PILLAR, a phase 2b study of the investigational hepatitis C virus (HCV) NS3/4A protease inhibitor TMC435 in treatment-naïve patients with chronic genotype 1 HCV, as part of a late-breaker oral presentation at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, CA, USA.

7 Nov 2011

Escitalopram reduces pain severity, interference in opioid-dependent patients

In what is believed to be the first study of its kind to demonstrate an association between the antidepressant escitalopram and improved general pain, researchers from Boston University School of Medicine (BUSM), have found that opioid-dependent patients treated with escitalopram experienced meaningful reductions in pain severity and pain interference during the first three months of therapy.

4 Nov 2011

Viewpoints: GOP intransigence on super committee; taxing health benefits would backfire; the need for care in defining essential benefits

There may be logic to Speaker John Boehner's insidious intransigence. Republicans keep saying no and Democrats keep offering more concessions. Super committee Republicans suggested instead a package based largely on cuts in Medicare, Medicaid and Social Security, combined with magical hundreds of billions they say would be produced by slashing assistance to the elderly and the vulnerable, by selling off government assets, and by the growth sparked by tax cuts.

3 Nov 2011

Americans overdosing on prescription pain killers

According to figures released by the Centers for Disease Control and Prevention (CDC) 40 Americans die from prescription painkiller abuse each day. Overdoses of opioid prescription drugs now kill more people in the U.S. than do overdoses from heroin and cocaine combined the report says. Twelve million Americans say they abused prescription drugs in the last year.

2 Nov 2011

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for NUCYNTA ER (tapentadol) extended-release tablets, an oral analgesic, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults.

31 Oct 2011

Merck announces results from ISENTRESS Phase III combination study on HIV-1

Merck, known as MSD outside the United States and Canada, today announced results of new exploratory pre-specified analyses from the ongoing STARTMRK Phase III study of its integrase inhibitor ISENTRESS (raltegravir) Tablets in combination therapy compared to efavirenz in combination therapy in previously untreated adult HIV-1-infected patients.

14 Oct 2011

Hydromorphone can be as effective as diacetylmorphine in treating heroin addiction

A clinical trial to test better treatment options for chronic heroin addiction is expected to begin in Vancouver at the end of this year. Led by researchers from Providence Health Care and the University of British Columbia, it's the only clinical trial of its kind in North America.

13 Oct 2011

Lightlake to begin opioid antagonist derived nasal spray Phase II trials in Binge Eating Disorder

Lightlake Therapeutics Inc., an early stage biopharmaceutical company currently developing a nasal spray for the treatment of overweight and obese patients with Binge Eating Disorder, today announced that its patient testing stage of the Phase II clinical trials will start August 26th, 2011

25 Aug 2011

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA and ACTIQ.

22 Jul 2011

IAS, UIPHP to launch VKC for injecting drug users living with HIV

As a part of its new initiative, Expanding Access to Opioid Substitution Therapy (OST) for People Who Inject Drugs in Eastern Europe and Central Asia (EECA), the International AIDS Society (IAS) will launch a Virtual Knowledge Centre (VKC) in partnership with the Ukrainian Institute on Public Health Policy.

21 Jul 2011

Novel vaccine for treating heroin addiction

Researchers at The Scripps Research Institute have developed a highly successful vaccine against a heroin high and have proven its therapeutic potential in animal models.

21 Jul 2011

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

Merck, known as MSD outside the United States and Canada, today announced final results from a Phase II clinical study, extending out to 240 weeks, of its integrase inhibitor ISENTRESS® (raltegravir) Tablets in combination therapy in previously untreated (treatment-naïve) adult HIV-1-infected patients.

18 Jul 2011

IAS, NIDA announce recipients of third annual joint research fellowships

The International AIDS Society (IAS) and the US National Institute on Drug Abuse (NIDA) today announced the recipients of their third annual joint research fellowships. Recipients of the prestigious awards will receive US$75,000 each to advance scientific understanding of the linkages between drug use and HIV while fostering multinational research.

13 Jul 2011

Roundup: Mass. doctors eye care management funds; Fla. groups fear Scott will block federal grants

It's clear from the data that hospitals and doctors can do a lot better at coordinating care for their patients. On the final day of hearings on controlling health care costs today, state officials estimated that at least $2 billion was spent in Massachusetts in 2009 on potentially avoidable emergency room visits, hospitalizations and readmissions.

2 Jul 2011

Centric Health to acquire DNPI Group assets

Centric Health Corporation, Canada's leading diversified healthcare company, today announced that it has entered into a definitive asset purchase agreement through a wholly owned subsidiary to acquire certain assets of Dedicated National Pharmacies Inc., Methadrug Clinic Limited and Union Medical Pharmacy Inc. from the court-appointed receiver of the DNPI Group, Grant Thornton Limited (the "Receiver").

27 Jun 2011